Disease Areas:
CoughDevice Types:
VitaloJAKThis Phase IIa, double-blind crossover study evaluated the efficacy, safety, and tolerability of eliapixant in 37 adult patients with refractory chronic cough attending specialist centers in the United Kingdom. The primary efficacy endpoint was change in cough frequency assessed over 24 hours using the Vitalograph VitaloJAK device.